1
|
Duan H, Sun X, Liao W, Petersen JL, Shi X. Proline as Lewis Base Catalyst: Diastereoselective Synthesis of Isoxazoline-N-oxide through [3 + 2] Cycloaddition. Org Lett 2008; 10:4113-6. [PMID: 18722449 DOI: 10.1021/ol801656y] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Haifeng Duan
- C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506
| | - Xiaohua Sun
- C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506
| | - Wenyan Liao
- C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506
| | - Jeffrey L. Petersen
- C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506
| | - Xiaodong Shi
- C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, West Virginia 26506
| |
Collapse
|
2
|
Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PYS, Quan ML, Knabb RM. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 2007; 24:43-51. [PMID: 17323133 DOI: 10.1007/s11239-007-0017-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2006] [Accepted: 01/26/2007] [Indexed: 10/23/2022]
Abstract
Coactivation of platelets and the blood coagulation cascade contributes to the pathophysiology of arterial thrombosis. Combination therapy with antiplatelet and anticoagulant drugs may be needed for maximizing the prevention and treatment of arterial thrombosis. Few studies have thoroughly investigated the combined antithrombotic and bleeding effects of these antithrombotic agents. We, therefore, evaluated the antithrombotic and bleeding profiles of dual and triple therapy with razaxaban, a direct factor Xa inhibitor, plus aspirin and/or clopidogrel in rabbit models of electrolytic injury-induced carotid artery thrombosis and cuticle bleeding time, respectively. Compounds were infused either IV or into the portal vein from 1 h before arterial injury or cuticle transection to the end of experiment. Carotid blood flow was used as a marker of antithrombotic effect. We first evaluated the antithrombotic potency of razaxaban, and examined its ex vivo effects on coagulation parameters to confirm its selectivity. Antithrombotic ED(50) of razaxaban averaged 0.22 +/- 0.05 mg/kg/h (n = 6). Razaxaban at 3 mg/kg/h IV produced full antithrombotic efficacy, increased significantly ex vivo activated partial thromboplastin time and prothrombin time by 2.2 +/- 0.1- and 2.3 +/- 0.1-fold, respectively, and inhibited ex vivo factor Xa activity significantly by 91 +/- 5% (n = 6, P < 0.05) without affecting ex vivo thrombin activity. Razaxaban at concentrations up to 10 muM did not alter in vitro platelet aggregation responses to ADP, gamma-thrombin or collagen. To identify additive or synergistic antithrombotic effects of the various combination therapies, we purposefully used marginally effective doses of razaxaban at 0.1 mg/kg/h, aspirin at 0.3 mg/kg/h and clopidogrel at 1 mg/kg/h. Dual combination of threshold doses of razaxaban and aspirin or clopidogrel produced an enhanced antithrombotic effect without further increases in bleeding time. When compared with dual therapy with aspirin and clopidogrel (38 +/- 5% increase in blood flow), addition of razaxaban increased blood flow to 75 +/- 5% without additional bleeding time effects (n = 6/group, P < 0.05). In summary, razaxaban was an effective antithrombotic agent in a rabbit model of arterial thrombosis. Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding.
Collapse
Affiliation(s)
- Pancras C Wong
- Department of Thrombosis Research, Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA.
| | | | | | | | | | | | | |
Collapse
|
3
|
Pd(0) catalyzed intramolecular alkylation: stereoselective synthesis of furan and isoxazoline-2-oxide analogs. Tetrahedron 2007. [DOI: 10.1016/j.tet.2006.11.066] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Hanson J, de Leval X, Kolh P, Supuran C, Pirotte B, Dogné JM. Update on GPIIb/IIIa antagonists. Expert Opin Ther Pat 2005. [DOI: 10.1517/13543776.13.8.1173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
5
|
Hamilton SF, Miller MW, Thompson CA, Dale GL. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. ACTA ACUST UNITED AC 2004; 143:320-6. [PMID: 15122176 DOI: 10.1016/j.lab.2004.02.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Platelets activated simultaneously with thrombin and collagen reveal a subpopulation of cells that express on their surfaces high levels of several alpha-granule proteins, including factor V and fibrinogen; these COAT platelets (collagen and thrombin-activated platelets) represent roughly 30% of the total population. Evidence of enhanced stability of proteins on the COAT-platelet surface was provided by the observation that PAC-1, a mAB recognizing the activated form of glycoprotein (GP) IIb/IIIa, did not inhibit fibrinogen binding to COAT-platelets. We therefore undertook a systematic evaluation of the effects of other GP IIb/IIIa inhibitors on the production of COAT platelets. Not only did GP IIb/IIIa antagonists fail to inhibit the retention of fibrinogen on COAT-platelets, but several actually increased the absolute percentage of COAT platelets produced. The increases over control values in the presence of eptifibatide, tirofiban, and DMP-802 were 1.36-, 1.20-, and 1.05-fold, respectively (P <.01 for each comparison). COAT-platelet production in the presence of abciximab was not significantly affected. However, platelet activation with thrombin plus ALB6, an Fc-receptor agonist, produces a product, referred to as FcRT platelets, that is indistinguishable from COAT platelets; all 4 GP IIb/IIIa antagonists tested potentiated formation of FcRT platelets. These findings indicate that fibrinogen binding to COAT platelets and FcRT platelets is not affected by available GP IIb/IIIa inhibitors. More importantly, our study demonstrates a potentiation of COAT-platelet production by some GP IIb/IIIa antagonists that may be relevant to the observation that long-term administration of orally available GP IIb/IIIa inhibitors not only failed to protect patients but actually increased the frequency of acute coronary events.
Collapse
Affiliation(s)
- Stephen F Hamilton
- College of Pharmacy, Department of Medicine, W.K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
| | | | | | | |
Collapse
|
6
|
Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415:175-9. [PMID: 11805836 DOI: 10.1038/415175a] [Citation(s) in RCA: 236] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Activated platelets bind numerous adhesive and procoagulant proteins by receptor-mediated processes. Although there is little evidence to suggest that these processes are heterogeneous in platelets, we previously found that platelets co-stimulated with collagen and thrombin express functional alpha-granule factor V only on a subpopulation of cells. Here we show that these cells, referred to as 'COAT-platelets', bind additional alpha-granule proteins, including fibrinogen, von Willebrand factor, thrombospondin, fibronectin and alpha2-antiplasmin. These proteins are all transglutaminase substrates, and inhibitors of transglutaminase prevent the production of COAT-platelets. A synthetic transglutaminase substrate (CP15) also binds to COAT-platelets, and analysis by high performance liquid chromatography/mass spectrometry shows that a product is formed with a relative molecular mass (Mr) equal to CP15 plus 176. Serotonin, an abundant component of platelet-dense granules, has an Mr of 176, and fibrinogen isolated from COAT-platelets contains covalently linked serotonin. Synthetic bovine serum albumin-(serotonin)6 binds selectively to COAT-platelets and also inhibits the retention of procoagulant proteins on COAT-platelets. These data indicate that COAT-platelets use serotonin conjugation to augment the retention of procoagulant proteins on their cell surface through an as yet unidentified serotonin receptor.
Collapse
Affiliation(s)
- George L Dale
- W. K. Warren Medical Research Institute and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Mousa SA, Bozarth JM, Naik UP, Slee A. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br J Pharmacol 2001; 133:331-6. [PMID: 11375248 PMCID: PMC1572788 DOI: 10.1038/sj.bjp.0703943] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
A number of non-peptide orally active RGD mimetic prodrug such as Orbofiban, Sibrafiban, SR121566, Roxifiban and others entered into the clinical evaluation stage. Some of these agents were terminated and some are still in clinical trials. The present study examined the platelet GPIIb/IIIa binding profiles for the active form of Roxifiban, Sibrafiban, SR121566 and Orbofiban using 3H-Roxifiban active form (XV459), 3H-DMP728, 125I-Echistatin, and 125I-Fibrinogen. Either DMP728, Orbofiban, Sibrafiban, SR121566 or Roxifiban active form as well as other RGD mimetic bind to the same binding site(s) on human platelets as evident from the competitive inhibition of binding of each other to human platelet. Additionally, Roxifiban active form competed with FITC labeled GPIIb/IIIa antagonist cyclic RGD peptidomimetic (XL086) as demonstrated using confocal microscopy technique. Roxifiban active form (XV459) demonstrated the highest potency in inhibiting 3H-XV459, 3H-DMP728, 125I-Echistatin, and 125I-Fibrinogen binding to human platelets as compared to the others. Structure activity relationship within the isoxazoline Roxifiban series showed that substituent at the alpha-carbon next to the carboxy terminal represents an exosite for the affinity binding to human platelets leading to slow platelet dissociation rate. These data indicated a distinct binding profile for Roxifiban (high affinity to both activated and resting platelets associated with a relatively slow K(off)) as compared to others. These differences might determine the pharmacodynamics and pharmackokinetics of the different GPIIb/IIIa antagonists.
Collapse
Affiliation(s)
- S A Mousa
- DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400, USA.
| | | | | | | |
Collapse
|
8
|
Mousa SA, Forsythe M, Bozarth J, Jin F, Confalone PN. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin. Coron Artery Dis 2000; 11:563-70. [PMID: 11023245 DOI: 10.1097/00019501-200010000-00008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To define the affinity and specificity of SJ874, a nonpeptide antiplatelet agent for platelet glycoprotein Ilb/IIIa integrin, and to determine the antiplatelet efficacy of SJ874 relative to those of glycoprotein IIbIIIa antagonists and aspirin. METHODS Binding affinity and specificity of SJ874 for platelet glycoprotein IIb/IIIa integrin were determined using integrin-mediated binding and adhesion assays with human cells. Additionally, the antiplatelet efficacy of SJ874 was determined and compared with those of other glycoprotein IIb/IIIa antagonists and aspirin using light-transmittance and laser-scattering aggregometry. RESULTS SJ874 inhibited aggregation of human platelets induced by 10 micromol/l adenosine diphosphate (ADP) with a concentration for half-maximal effect of 0.046 +/- 0.005 micromol/l using light-transmittance aggregometry. Using laser-scattering aggregometry, SJ874 was found to totally inhibit formation both of micro-aggregates and of macro-aggregates induced either by ADP or by epinephrine. In contrast, administration of 325 mg aspirin to normal healthy volunteers attenuated formation of macro-aggregates but not micro-aggregates. SJ874 inhibited binding of [125I]-fibrinogen to activated (by ADP, epinephrine, and arachidonic acid at concentrations of 100 micromol/l each) gel-filtered human platelets with a concentration for half-maximal effect of 0.0012 +/- 0.0005 micromol/l. SJ874 was demonstrated to associate more tightly with resting human platelets than did DMP754 [1] and slightly less tightly than did DMP802 [2]. SJ874 was demonstrated to exhibit a high degree of specificity for platelet glycoprotein IIb/IIIa (alphaIIb/beta3) integrin compared with other known integrins, including alphavbeta3, alphavbeta5, and alpha5beta1 (concentration for half-maximal effect > 100 micromol/l). CONCLUSION SJ874 is a potent and specific platelet glycoprotein IIb/IIIa antagonist with high affinity for and tight association with human platelets. These data suggest that SJ874 might have good antiplatelet utility for inhibiting formation both of platelet micro-aggregates and of macro-aggregates of platelets and a long duration of action in humans due to its slow dissociation from human platelets.
Collapse
Affiliation(s)
- S A Mousa
- DuPont Pharmaceuticals Co., Wilmington, Delaware 19880-0400, USA.
| | | | | | | | | |
Collapse
|
9
|
Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999; 19:2835-40. [PMID: 10591658 DOI: 10.1161/01.atv.19.12.2835] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- A T Nurden
- UMR 5533 CNRS and the Unité des Soins Intensifs (C.D.-J.), Institut Fédératif de Recherche "Coeur-Vaisseaux-Thrombose," Hôpital Cardiologique, Pessac, France.
| | | | | | | |
Collapse
|
10
|
Barrett JS, Yu J, Kapil R, Padovani P, Brown F, Ebling WF, Corjay MH, Reilly TM, Bozarth JM, Mousa SA, Pieniaszek HJ. Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig. Biopharm Drug Dispos 1999; 20:309-18. [PMID: 10701702 DOI: 10.1002/(sici)1099-081x(199909)20:6<309::aid-bdd190>3.0.co;2-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The disposition of XV459, a potent, selective GP IIb/IIIa antagonist, has been examined following intravenous administration of XP280, the benzenesulphonate salt, and 3H-SA202, the trifluroacetic acid salt, to male guinea pigs. A liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for XV459 quantitation in guinea pig plasma with an LLOQ of 0.1 ng/mL. Intravenous infusions (30 min) of XP280 at doses of 0.5 and 2.0 microg/kg were administered to guinea pigs which were sequentially sacrificed at 0.5, 1, 1.5, 4, 8, 12, 24, 48 and 72 h postinitiation of infusion. Maximum total (unbound and GP IIb/IIIa displaced) XV459 plasma concentration of approximately 3.5 microg/mL was obtained at the 2.0 microg/kg dose. Pooling individual concentration-time data yielded a systemic clearance of 1.42 mL/min/kg, Vss of 0.24 L/kg, and a terminal half-life of 2.8 h in the guinea pig at the 0.5 microg/kg dose. The 2.0 microg/kg dose yielded XV459 exposure that was less than proportional to the previous dose. Similar behaviour has been observed in human trials. Cumulative (up to 72 h) urinary and faecal recovery of total radioactivity was 66.4 and 11.2%, respectively. The time course of spleen, marrow and whole blood radioactivity profiles was similar, suggesting that XV459 was not preferentially sequestered on non-plasma GP IIb/IIIa binding sites. Tissue to blood ratios of 20.7 and 8.3 for the spleen and bone marrow, respectively, indicate that increased (relative to blood) exposure was evident for sites containing the GP IIb/IIIa receptor. In vitro studies confirmed the similarity of XV459 binding to both resting and activated platelets in the guinea pig and humans. Given the comparability of dissociation rate constants and IC50s based on in vitro platelet aggregation, human dosimetry estimates should assume similar partitioning of radiolabelled XV459 as in the guinea pig. These results suggest that the guinea pig may indeed be an appropriate animal model for pharmacokinetic and distribution studies with DMP754; in conjunction with recent pharmacological findings with GP IIb/IIIa antagonists, our results suggest that the guinea pig may be the rodent species of choice for preclinical studies with some other GP IIb/IIIa antagonists.
Collapse
Affiliation(s)
- J S Barrett
- Drug Metabolism and Pharmacokinetics Department, DuPont Pharmaceuticals, Newark, DE 19714, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Confalone PN, Jin F, Mousa SA. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines. Bioorg Med Chem Lett 1999; 9:55-8. [PMID: 9990456 DOI: 10.1016/s0960-894x(98)00686-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A series of isoxazolidines has been synthesized as mimetics of the RGD sequence and was evaluated as antagonists of the platelet glycoprotein IIb/IIIa receptor. These compounds were shown to be highly potent GPIIb/IIIa antagonists, exhibiting submicromolar potencies.
Collapse
Affiliation(s)
- P N Confalone
- DuPont Pharmaceuticals Company, DuPont Experimental Station, Wilmington, DE 19880-0336, USA
| | | | | |
Collapse
|